Early detection and risk assessment: Proceedings and recommendations from the workshop on epigenetics in cancer prevention

Annals of the New York Academy of Sciences

Volumn 983, Issue , 2003, Pages 298-319

  Verma, Mukesh ^a   Dunn, Barbara K ^a   Ross, Sharon ^a   Jain, Pawan ^b   Wang, Wendy ^a   Hayes, Richard ^a   Umar, Asad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Acetylation; Biomarker; Cancer detection; Epigenetics; Methylation; Microarray; Prevention; Risk assessment

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

AGING; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CHROMATIN CONDENSATION; CONFERENCE PAPER; DEACETYLATION; DNA METHYLATION; EARLY DIAGNOSIS; GENE EXPRESSION REGULATION; GENOME IMPRINTING; HUMAN; METHYLATION; MOLECULAR BIOLOGY; MUTATION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT;

EID: 0037356285     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb05984.x     Document Type: Conference Paper

References (81)

1. HERMAN, J.G. & S.B. BAYLIN. 2000. Promoter-region hypermethylation and gene silencing in human cancer. Curr. Top. Microbiol. Immunol. 249: 35-54.
2. VIRMANI, A.K. et al. 2002. Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol. Biomarkers Prev. 11: 291-297.
3. BELINSKY, S.A. 2002. Epigenetics is alive and growing. Trends Mol. Med. 8: 53-54.
4. FRUHWALD, M.C. & C. PLASS. 2002. Global and gene-specific methylation patterns in cancer: aspects of tumor biology and clinical potential. Mol. Genet. Metab. 75: 1-16.
5. JONES, P.A. & S.B. BAYLIN. 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3: 415-428.
6. JONES, P.A. 2002. DNA methylation and cancer. Oncogene 21: 5358-5360.
7. JOHNSTONE, R.W. 2002. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1: 287-299.
8. LITT, M.D. et al. 2001. Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus. Science 293: 2453-2455.
9. LITT, M.D. et al. 2001. Transitions in histone acetylation reveal boundaries of three separately regulated neighboring loci. EMBO J. 20: 2224-2235.
10. NOMA, K., C.D. ALLIS & S.I. GREWAL. 2001. Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science 293: 1150-1155.
11. JENUWEIN, T. & C.D. ALLIS. 2001. Translating the histone code. Science 293: 1074-1080.
12. JONES, P.L. et al. 1998. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19: 187-191.
13. JONES, P.A. & P.W. LAND. 1999. Cancer epigenetics comes of age. Nat. Genet. 21: 163-167.
14. KRUHLAK, M.J. et al. 2001. Regulation of global acetylation in mitosis through loss of histone acetyltransferases and deacetylases from chromatin. J. Biol. Chem. 276: 38307-38319.
15. CHANDLER, L.A. et al. 1986. Patterns of DNA methylation and gene expression in human tumor cell lines. Cancer Res. 46: 2944-2949.
16. CAMERON, E.E. et al. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21: 103-107.
17. FINNIN, M.S. et al. 1999. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193.
18. PIKAART, M.J., F. RECILLAS-TARGA & G. FELSENFELD. 1998. Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev. 12: 2852-2862.
19. LANTRY, L.E. et al. 1999. 5-Aza-2′-deoxycytidine is chemopreventive in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis 20: 343-346.
20. LIANG, G. et al. 2002. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res. 62: 961-966.
21. BAYLIN, S. & T.H. BESTOR. 2002. Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1: 299-305.
22. WATSON, R.E. & J.I. GOODMAN. 2002. Epigenetics and DNA methylation come of age in toxicology. Toxicol. Sci. 67: 11-16.
23. GARBER, K. 2002. Silence of the genes: cancer epigenetics arrives. J. Natl. Cancer Inst. 94: 793-795.
24. URNOV, F.D. 2002. Methylation and the genome: the power of a small amendment. J. Nutr. 132: 2450S-2456S.
25. URNOV, F.D. & A.P. WOLFFE. 2001. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene 20: 2991-3006.
26. URNOV, F.D. & A.P. WOLFFE. 2001. Above and within the genome: epigenetics past and present. J. Mammary Gland Biol. Neoplasia 6: 153-167.
27. BIRD, A. 2001. Molecular biology. Methylation talk between histones and DNA. Science. 294: 2113-2115.
28. FEINBERG, A.P. 2001. Cancer epigenetics takes center stage. Proc. Natl. Acad. Sci. USA 98: 392-394.
29. BAYLIN, S.B. & J.G. HERMAN. 2001. Promoter hypermethylation - can this change alone ever designate true tumor suppressor gene function? J. Natl. Cancer Inst. 93: 664-665.
30. BAYLIN, S. 2001. DNA methylation and epigenetic mechanisms of carcinogenesis. Dev. Biol. (Basel) 106: 85-87; discussion 143-160.
31. ROSAS, S.L. et al. 2001. Promoter hypermethylation patterns of p 16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61: 939-942.
32. JERONIMO, C. et al. 2002. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 11: 445-450.
33. JERONIMO, C. et al. 2001. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl. Cancer Inst. 93: 1747-1752.
34. BRABENDER, J. et al. 2001. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20: 3528-3532.
35. AKHTAR, M. et al. 2001. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res. 61: 2399-2403.
36. CHEN, J. et al. 2001. Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lyric transactivator. Proc. Natl. Acad. Sci. USA 98: 4119-4124.
37. VERMA, M., P.F. LAMBERT & S.K. SRIVASTAVA. 2001. Meeting highlights: National Cancer Institute workshop on molecular signatures of infectious agents. Dis. Markers 17: 191-201.
38. TAKACS, M. et al. 2001. Epigenetics of latent Epstein-Barr virus genomes: high resolution methylation analysis of the bidirectional promoter region of latent membrane protein 1 and 2B genes. Biol. Chem. 382: 699-705.
39. LENGAUER, C. & J.P. ISSA. 1998. The role of epigenetics in cancer. DNA Methylation, Imprinting and the Epigenetics of Cancer - an American Association for Cancer Research Special Conference. Las Croabas, Puerto Rico, 12-16 1997 December. Mol. Med. Today 4: 102-103.
40. ISSA, J.P. 2000. The epigenetics of colorectal cancer. Ann. N.Y. Acad. Sci. 910: 140-153; discussion 153-155.
41. TOYOTA, M. et al. 2000. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc. Natl. Acad. Sci. USA 97: 710-715.
42. TOYOTA, M. et al. 1999. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 59: 5438-5442.
43. TOYOTA, M. & J.P. ISSA. 1999. CpG island methylator phenotypes in aging and cancer. Semin. Cancer Biol. 9: 349-357.
44. TOYOTA, M. et al. 1999. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 96: 8681-8686.
45. TYCKO, B. & J. ASHKENAS. 2000. Epigenetics and its role in disease. J. Clin. Invest. 105: 245-246.
46. CUI, H. et al. 2001. Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res. 61: 4947-4950.
47. CIU, H. et al. 1997. Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms' tumorigenesis. Cancer Res. 57: 4469-4473.
48. SAKATANI, T. et al. 2001. Epigenetic heterogeneity at imprinted loci in normal populations. Biochem. Biophys. Res. Commun. 283: 1124-1130.
49. YEH, A. et al. 2002. Chromosome arm 16q in Wilms tumors: Unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene. Genes Chromosomes Cancer 35: 156-163.
50. LYNCH, C.A. et al. 2002. Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation. Mol. Cancer 1: 2.
51. KAWAKAMI, M. et al. 1999. Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int. J. Oncol. 15: 715-720.
52. COSTA, M. & C.B. KLEIN. 1999. Nickel carcinogenesis, mutation, epigenetics, or selection. Environ. Health Perspect. 107: A438-439.
53. COSTA, M. et al. 2002. The role of oxidative stress in nickel and chromate genotoxicity. Mol. Cell. Biochem. 234-235: 265-275.
54. COSTA, M. et al. 2001. Molecular biology of nickel carcinogenesis. Mol. Cell. Biochem. 222: 205-211.
55. SALNIKOW, K. & M. COSTA. 2000. Epigenetic mechanisms of nickel carcinogenesis. J Environ. Pathol. Toxicol. Oncol. 19: 307-318.
56. HERMAN, J.G. et al. 1996. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93: 9821-9826.
57. HERMAN, J.G. et al. 1997. Distinct patterns of inactivation of p151NK4B and p 16INK4A characterize the major types of hematological malignancies. Cancer Res. 57: 837-841.
58. HERMAN, J.G. 1999. p16(INK4): involvement early and often in gastrointestinal malignancies. Gastroenterology 116: 483-485.
59. ALWORTH, L.C. et al. 2002. Uterine responsiveness to estradiol and DNA methylation are altered by fetal exposure to diethylstilbestrol and methoxychlor in CD-1 mice: effects of low versus high doses. Toxicol. Appl. Pharmacol. 183: 10-22.
60. YAN, P.S. et al. 2002. Applications of CpG island microarrays for high-throughput analysis of DNA methylation. J. Nutr. 132: 2430S-2434S.
61. WEI, S.H. et al. 2002. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res. 8: 2246-2252.
62. YAN, P.S. et al. 2002. Use of CpG island microarrays to identify colorectal tumors with a high degree of concurrent methylation. Methods 27: 162-169.
63. SHI, H. et al. 2002. Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Res. 62: 3214-3220.
64. GITAN, R.S. et al. 2002. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res. 12: 158-164.
65. YAN, P.S. et al. 2001. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res. 61: 8375-8380.
66. EADS, C.A. et al. 2001. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61: 3410-3418.
67. EADS, C.A. et al. 2000. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 60: 5021-5026.
68. EADS, C. A. et al. 2000. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28: E32.
69. EADS, C.A., A.E. NICKEL & P.W. LAIRD. 2002. Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic mice. Cancer Res. 62: 1296-1299.
70. SRINIVAS, P.R. et al. 2002. Proteomics for cancer biomarker discovery. Clin. Chem. 48: 1160-1169.
71. VERMA, M. et al. 2001. Proteomic approaches within the NC1 early detection research network for the discovery and identification of cancer biomarkers. Ann. N.Y. Acad. Sci. 945: 103-115.
72. SATO, F. et al. 2002. Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res. 62: 1148-1151.
73. HIRSCH, F.R. et al. 2001. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin. Cancer Res. 7: 5-22.
74. SZVF, M. 2002. Utilization of antisense oligonucleotides to study the role of 5-cytosine DNA methyltransferase in cellular transformation and oncogenesis. Methods 27: 184-191.
75. REID, G.K., J.M. BESTERMAN & A.R. MACLEOD. 2002. Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment. Curr. Opin. Mol. Ther. 4: 130-137.
76. LIN, X. et al. 2001. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 61: 8611-8616.
77. LIN, X. et al. 2001. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. 159: 1815-1826.
78. GRATCHEV, A. et al. 2001. Regulation of the intestinal mucin MUC2 gene expression in vivo: evidence for the role of promoter methylation. Cancer Lett. 168: 71-80.
79. SONG, J. et al. 2000. Chemopreventive effects of dietary folate on intestinal polyps in Apc+/-Msh2-/- mice. Cancer Res. 60: 3191-3199.
80. OUE, N. et al. 2002. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J. Pathol. 198: 55-59.
81. MARKOWITZ, S. et al. 1995. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338.